Back to search results

Lu-TARGO: A Study of LNTH-2403 for Relapsed/Refractory Osteosarcoma

This study, called Lu-TARGO, is testing a new treatment called LNTH-2403 for people with osteosarcoma (a type of bone cancer) that has come back or not responded to previous treatments (relapsed/refractory). The study aims to find the safest and most effective dose of LNTH-2403. Researchers will also look at how well LNTH-2403 works against the cancer. You may be able to join if you are 12 years or older and have a confirmed diagnosis of relapsed/refractory osteosarcoma. The study is currently recruiting about 55 participants, but its exact status is unclear.

Study design
This is a multi-center, non-randomized, open-label study with two phases: a dose-finding phase and a phase to further test the treatment. It plans to enroll 55 participants.
What's involved
LNTH-2403 is given once every 8 weeks, with potential for other schedules. The study will measure safety and how the drug moves through the body.
Compensation
Not stated in the trial record.
Follow-up
The study will assess preliminary anti-neoplastic activity for up to 4 months after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07357519

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Recruiting
PHASE1Ages 12+InterventionalTreatment
Lantheus Medical Imaging
~55 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:LNTH2403 Phase 1 dosePhase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To identify the maximum tolerated dose (MTD) of LNTH-2403 in participants with R/R osteosarcoma (Ph1)
Measured over From enrollment to the end of treatment at 8 weeks
+2 more outcomes measured

Conditions

Relapsed / Refractory Osteosarcoma

Explore related trials

Osteosarcoma

Where it's being run

2 sites across 2 states
California1
Massachusetts1

Who to contact

Kerri Sforzo
[email protected]
978-671-8886
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • To identify the maximum tolerated dose (MTD) of LNTH-2403 in participants with R/R osteosarcoma (Ph1)From enrollment to the end of treatment at 8 weeks

    Incidence of DLTs during the first 8 weeks (DLT evaluation window) after the first dose of LNTH-2403

  • To evaluate the safety and tolerability profile of LNTH-2403 in participants with R/R osteosarcoma (Ph1)From enrollment to the end of treatment at 8 weeks

    Type, frequency, severity, timing, and relationship to LNTH-2403 of all Treatment-emergent adverse event, (TEAEs) and Serious adverse events, (SAEs)

  • To assess the preliminary anti-neoplastic activity of LNTH-2403 in participants with R/R osteosarcoma (Ph2)From enrollment to Event-Free Survival (EFS) at 4 months

    Event-Free Survival (EFS) at 4 months